次全视网膜冷凝联合抗代谢药物治疗新生血管性青光眼

Combination treatment with subtotal retinal cryocoagulation and antimetabolites for neovascular glaucoma

目的： 探讨新生血管性青光眼尤其晚期病例的治疗方法。方法： 将 ４０ 例新生血管性青光眼随机分为次全视网膜冷凝 （ Ｓ Ｒ Ｃ）组 ２３ 例 （２３ 只眼）， 单纯用 Ｓ Ｒ Ｃ或联合抗青光眼手术， 对照组 １７ 例 （１７ 只眼） 行抗青光眼手术。两组术后均局部应用 ５— Ｆｕ 和地塞米松。术后随访 １ 月～５ 年， 平均 ６ 个月。结果： Ｓ Ｒ Ｃ组的治疗成功率 （７３９％ ） 高于对照组 （４１２％ ）， 差异有显著性 （ Ｐ＜ ００５）。结论：单纯次全视网膜冷凝术或联合抗青光眼手术及术后抗代谢药物的应用是一种治疗新生血管性青光眼的较有效的方法， 本方法特别适用于屈光间质混浊的晚期的病例。

Objective:To investigate the treatment of neovascular glaucoma(NVG).Methods:23 cases(23 eyes)with NVG were treated by subtotal retinal cryocoagulation(SRC)only or SRC combined with antiglaucoma surgery,and 17 cases(17 eyes)with NVG were treated by antiglaucoma surgey as controls.All cases were treated by 5 Fu and dexamethasone after surgery.The follow up periods were one month to 5 years.Results;The rate of curative effects in SRC group (73 9%)was significantly higher than that of the control group(41 2%)(P<0 05).Conclusion:It is suggested that SRC combined with antiglaucoma surgery may increase the curative effects of NVG,especially suitable for cases with optic media opacification and later stage.